1
|
Fürstenau M, Bahlo J, Fink AM, Lange E, Dreger P, Dreyling M, Hess G, Ritgen M, Kneba M, Döhner H, Stilgenbauer S, Wendtner CM, Goede V, Fischer K, Böttcher S, Hallek M, Eichhorst B. Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia. Leukemia 2019; 34:924-928. [PMID: 31611627 DOI: 10.1038/s41375-019-0597-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2019] [Revised: 08/30/2019] [Accepted: 09/30/2019] [Indexed: 11/10/2022]
Affiliation(s)
- M Fürstenau
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
| | - J Bahlo
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany
| | - A M Fink
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany
| | - E Lange
- Evangelisches Krankenhaus Hamm, Hamm, Germany
| | - P Dreger
- Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany
| | - M Dreyling
- Department of Internal Medicine III, University Hospital of the Ludwig Maximilians University Munich, Munich, Germany
| | - G Hess
- Department of Hematology, Medical Oncology and Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - M Ritgen
- Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany
| | - M Kneba
- Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany
| | - H Döhner
- Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
| | - S Stilgenbauer
- Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.,Department of Hematology, Oncology and Rheumatology and José Carreras Center for Immuno and Gene Therapy, Saarland University Medical School, Homburg/Saar, Germany
| | - C M Wendtner
- Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, München Klinik Schwabing, Munich, Germany
| | - V Goede
- Oncogeriatric Unit, Department of Geriatric Medicine, St. Marien Hospital, Cologne, Germany
| | - K Fischer
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany
| | - S Böttcher
- Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany.,Medical Clinic III, Hematology, Oncology and Palliative Medicine, Rostock University Medical Center, Rostock, Germany
| | - M Hallek
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.,Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Disease (CECAD), University of Cologne, Cologne, Germany
| | - B Eichhorst
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
| |
Collapse
|
2
|
Tausch E, Bahlo J, Robrecht S, Schneider C, Bloehdorn J, Schrell S, Galler C, Al-Sawaf O, Fink A, Eichhorst B, Kreuzer K, Tandon M, Humphrey K, Jiang Y, Schary W, Porro Lurà M, Döhner H, Fischer K, Hallek M, Stilgenbauer S. GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORABMUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY Best abstract submitted by a young investigator / travel grant recipient. Hematol Oncol 2019. [DOI: 10.1002/hon.53_2629] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- E. Tausch
- Department of Internal Medicine 3; Ulm University; Ulm Germany
| | - J. Bahlo
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital Cologne; Cologne Germany
| | - S. Robrecht
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital Cologne; Cologne Germany
| | - C. Schneider
- Department of Internal Medicine 3; Ulm University; Ulm Germany
| | - J. Bloehdorn
- Department of Internal Medicine 3; Ulm University; Ulm Germany
| | - S. Schrell
- Department of Internal Medicine 3; Ulm University; Ulm Germany
| | - C. Galler
- Department of Internal Medicine 3; Ulm University; Ulm Germany
| | - O. Al-Sawaf
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital Cologne; Cologne Germany
| | - A. Fink
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital Cologne; Cologne Germany
| | - B. Eichhorst
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital Cologne; Cologne Germany
| | - K. Kreuzer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital Cologne; Cologne Germany
| | - M. Tandon
- Clinical Development Oncology; Roche; Welwyn Garden City United Kingdom
| | - K. Humphrey
- Clinical Development Oncology; Roche; Welwyn Garden City United Kingdom
| | - Y. Jiang
- Oncology Biomarker Development; Genentech; South San Francisco United States
| | - W. Schary
- Oncology; Abbvie Inc; North Chicago United States
| | - M. Porro Lurà
- Pharmaceuticals Division; F. Hoffmann - La Roche Ltd; Basel Switzerland
| | - H. Döhner
- Department of Internal Medicine 3; Ulm University; Ulm Germany
| | - K. Fischer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital Cologne; Cologne Germany
| | - M. Hallek
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital Cologne; Cologne Germany
| | - S. Stilgenbauer
- Department of Internal Medicine 3; Ulm University; Ulm Germany
| |
Collapse
|
3
|
Langerbeins P, Bahlo J, Rhein C, Gerwin H, Cramer P, Fürstenau M, Al-Sawaf O, von Tresckow J, Fink A, Kreuzer K, Vehling-Kaiser U, Tausch E, Müller L, Eckart M, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Wendtner C, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M. IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE-BLIND RANDOMIZED CLL12 TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.7_2629] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- P. Langerbeins
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | - J. Bahlo
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | - C. Rhein
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | - H. Gerwin
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | - P. Cramer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | - M. Fürstenau
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | - O. Al-Sawaf
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | - J. von Tresckow
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | - A.M. Fink
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | - K. Kreuzer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | | | - E. Tausch
- Internal Medicine III; University Hospital; Ulm Germany
| | - L. Müller
- Hämatologie und Onkologie; Studienzentrum UnterEms; Leer Germany
| | - M. Eckart
- Hämatologie und Onkologie; Onkologische Schwerpunktpraxis; Erlangen Germany
| | - R. Schlag
- Hämatologie und Onkologie; Gemeinschaftspraxis; Würzburg Germany
| | - W. Freier
- Hämatologie und Onkologie; Medicinum; Hildesheim Germany
| | - T. Gaska
- Klinik für Hämatologie und Onkologie; Brüderkrankenhaus St. Josef; Paderborn Germany
| | - C. Balser
- Hämatologie und Onkologie; Internistische Praxis; Marburg Germany
| | - M. Reiser
- PIOH; Praxis Internistischer Onkologie und Hämatologie; Köln Germany
| | - M. Stauch
- Hämatologie; Onkologie, Gerinnung; Ambulantes Zentrum Kronach Germany
| | - C. Wendtner
- Department I of Internal Medicine, Munich Clinic Schwabing; Academic Teaching Hospital of University of Munich; Munich Germany
| | - K. Fischer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | - S. Stilgenbauer
- Internal Medicine I; University of Saarland; Homburg Germany
| | - B. Eichhorst
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| | - M. Hallek
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn; University Hospital; Cologne Germany
| |
Collapse
|
4
|
Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter M, Herling C, De Paoli L, Delgado J, Gentile M, Doubek M, Mauro F, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Moia R, Gerber B, Zucca E, Ghielmini M, Cavalli F, Stüssi G, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foà R, Pospisilova S, Morabito F, Wierda W, Montserrat E, Gaidano G, Hallek M, Rossi D. INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (IPS-A). Hematol Oncol 2019. [DOI: 10.1002/hon.51_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- A. Condoluci
- Experimental Hematology; Institute of Oncology Research; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - L. Terzi di Bergamo
- Experimental Hematology; Institute of Oncology Research; Bellinzona Switzerland
| | - P. Langerbeins
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - M. Hoechstetter
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - C. Herling
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - L. De Paoli
- Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - J. Delgado
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - M. Gentile
- Hematology; Azienda Ospedaliera (AO) of Cosenza; Cosenza Italy
| | - M. Doubek
- Hematology and Oncology; University Hospital of Brno; Brno Czech Republic
| | - F.R. Mauro
- Hematology; Sapienza University; Rome Italy
| | - G. Chiodin
- Hematology; Southampton University; Southampton United Kingdom
| | - M. Mattsson
- Immunology; Genetics and Pathology, Uppsala University; Uppsala Sweden
| | - J. Bahlo
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - G. Cutrona
- Hematology; IRCCS Ospedale Policlinico San Martino; Genoa Italy
| | - J. Kotaskova
- Hematology and Oncology; University Hospital of Brno; Brno Czech Republic
| | - C. Deambrogi
- Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - R. Moia
- Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - B. Gerber
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - E. Zucca
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - M. Ghielmini
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - F. Cavalli
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - G. Stüssi
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - A. Neri
- Hematology; University of Milan; Milan Italy
| | | | - R. Rosenquist
- Immunology; Genetics and Pathology, Uppsala University; Uppsala Sweden
| | - F. Forconi
- Hematology; Southampton University; Southampton United Kingdom
| | - R. Foà
- Hematology; Sapienza University; Rome Italy
| | - S. Pospisilova
- Hematology and Oncology; University Hospital of Brno; Brno Czech Republic
| | - F. Morabito
- Hematology; Augusta Victoria Hospital; Jerusalem Israel
| | - W.G. Wierda
- MD Anderson Cancer Center; University of Texas; Houston United States
| | - E. Montserrat
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - G. Gaidano
- Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - M. Hallek
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - D. Rossi
- Experimental Hematology; Institute of Oncology Research; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| |
Collapse
|
5
|
Tausch E, Bahlo J, Robrecht S, Schneider C, Bloehdorn J, Schrell S, Galler C, Al-Sawaf O, Fink AM, Eichhorst B, Kreuzer KA, Tandon M, Humphrey K, Jiang Y, Schary W, Porro Lurà M, Döhner H, Fischer K, Hallek M, Stilgenbauer S. S105 GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY. Hemasphere 2019. [DOI: 10.1097/01.hs9.0000558640.93333.00] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
6
|
Fischer K, Porro Lurà M, Al-Sawaf O, Bahlo J, Fink A, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati A, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto L, Utoft Niemann C, Weinkove R, Robinson S, Kipps T, Boettcher S, Tausch E, Schary W, Eichhorst B, Wendtner C, Langerak A, Kreuzer K, Goede V, Stilgenbauer S, Mobasher M, Ritgen M, Hallek M. FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES. Hematol Oncol 2019. [DOI: 10.1002/hon.52_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- K. Fischer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - M. Porro Lurà
- Pharmaceuticals Division; PDGo, F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - O. Al-Sawaf
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - J. Bahlo
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - A. Fink
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - M. Tandon
- Clinical Development Oncology; Roche Products Limited; Welwyn Garden City United Kingdom
| | - M. Dixon
- Biostatistics; Roche Products Limited; Welwyn Garden City United Kingdom
| | - S. Robrecht
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - S. Warburton
- Product Development - Oncology; Roche Products Limited; Welwyn Garden City United Kingdom
| | - K. Humphrey
- Clinical Development Oncology; Roche Products Limited; Welwyn Garden City United Kingdom
| | - O. Samoylova
- Hematology Department; Regional Clinical Hospital N.A. Semashko; Nizhny Novgorod Russian Federation
| | - A.M. Liberati
- Division of Onco-Hematology; Santa Maria Terni Hospital, University of Perugia; Perugia Italy
| | - J. Pinilla-Ibarz
- Department of Malignant Hematology; H. Lee Moffitt Cancer Center & Research Institute; Tampa FL United States
| | - S. Opat
- Haematology Department; School of Clinical Sciences at Monash Health; Monash University Victoria Australia
| | - L. Sivcheva
- First Internal Department; MHAT Hristo Botev; AD, Vratsa Bulgaria
| | - K. Le Dû
- Hematology Department; Clinique Victor Hugo; Le Mans France
| | - L.M. Fogliatto
- Department of Hematology; Hospital de Clínicas de Porto Alegre; Porto Alegre Brazil
| | - C. Utoft Niemann
- Department of Hematology; Rigshospitalet, Copenhagen University Hospital; Copenhagen Denmark
| | - R. Weinkove
- Wellington Blood & Cancer Centre; Capital & Coast District Health Board, Wellington, New Zealand and Cancer Immunotherapy Programme, Malaghan Institute of Medical Research; Wellington New Zealand
| | - S. Robinson
- Department of Medicine; Division of Hematology, QEII Health Sciences Center; Halifax NS Canada
| | - T.J. Kipps
- Moores Cancer Center; UC San Diego Health; San Diego CA United States
| | - S. Boettcher
- Department III of Internal Medicine; University Hospital Rostock; Rostock Germany
| | - E. Tausch
- Department III of Internal Medicine; Ulm University; Ulm Germany
| | - W.L. Schary
- Clinical Development Oncology; AbbVie Inc.; North Chicago IL United States
| | - B. Eichhorst
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - C. Wendtner
- Department of Hematology; Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine; Klinikum Schwabing Munich Germany
| | - A.W. Langerak
- Department of Immunology; Laboratory Medical Immunology, Erasmus MC; Rotterdam Netherlands
| | - K. Kreuzer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - V. Goede
- Oncogeriatric Unit; Dept. of Geriatric Medicine, St. Marien Hospital; Cologne Germany
| | - S. Stilgenbauer
- Department III of Internal Medicine, Ulm University, Ulm, Germany and Department for Hematology, Oncology and Rheumatology; Saarland University Medical School; Homburg/Saar Germany
| | - M. Mobasher
- Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
| | - M. Ritgen
- Department II of Internal Medicine; Campus Kiel, University of Schleswig-Holstein; Kiel Germany
| | - M. Hallek
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital, Cologne, CECAD (Cluster of Excellence on Cellular Stress Responses in Aging-Associated Diseases); University of Cologne; Cologne Germany
| |
Collapse
|
7
|
Al-Sawaf O, Lilienweiss E, Bahlo J, Robrecht S, Fink A, Patz M, Tandon M, Humphrey K, Jiang Y, Schary W, Porro Lurà M, Ritgen M, Tausch E, Stilgenbauer S, Eichhorst B, Fischer K, Hallek M, Kreuzer K. HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.68_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- O. Al-Sawaf
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - E. Lilienweiss
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - J. Bahlo
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - S. Robrecht
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - A. Fink
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - M. Patz
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - M. Tandon
- Clinical Development Oncology; Roche Products Limited; Welwyn Garden City United Kingdom
| | - K. Humphrey
- Clinical Development Oncology; Roche Products Limited; Welwyn Garden City United Kingdom
| | - Y. Jiang
- Oncology Biomarker Development; Genentech Inc.; South San Francisco CA United States
| | - W. Schary
- Clinical Development; Oncology, AbbVie Inc.; North Chicago IL United States
| | - M. Porro Lurà
- Pharmaceuticals Division, PDGo; F. Hoffmann-La Roche Ltd.; Basel Switzerland
| | - M. Ritgen
- Department II of Internal Medicine, Campus Kiel; University of Schleswig-Holstein; Kiel Germany
| | - E. Tausch
- Department III of Internal Medicine; Ulm University; Ulm Germany
| | - S. Stilgenbauer
- Department III of Internal Medicine, Ulm University, Ulm, Germany, and Department for Hematology, Oncology and Rheumatology; Saarland University Medical School; Homburg/Saar Germany
| | - B. Eichhorst
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - K. Fischer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| | - M. Hallek
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital, Cologne, CECAD (Cluster of Excellence on Cellular Stress Responses in Aging-Associated Diseases); University of Cologne; Cologne Germany
| | - K. Kreuzer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; University Hospital; Cologne Germany
| |
Collapse
|
8
|
Klymenko T, Bloehdorn J, Bahlo J, Robrecht S, Akylzhanova G, Cox K, Estenfelder S, Wang J, Edelmann J, Strefford JC, Wojdacz TK, Fischer K, Hallek M, Stilgenbauer S, Cragg M, Gribben J, Braun A. Lamin B1 regulates somatic mutations and progression of B-cell malignancies. Leukemia 2018; 32:364-375. [PMID: 28804121 PMCID: PMC5808072 DOI: 10.1038/leu.2017.255] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2017] [Revised: 07/07/2017] [Accepted: 07/31/2017] [Indexed: 12/24/2022]
Abstract
Somatic hypermutation (SHM) is a pivotal process in adaptive immunity that occurs in the germinal centre and allows B cells to change their primary DNA sequence and diversify their antigen receptors. Here, we report that genome binding of Lamin B1, a component of the nuclear envelope involved in epigenetic chromatin regulation, is reduced during B-cell activation and formation of lymphoid germinal centres. Chromatin immunoprecipitation-Seq analysis showed that kappa and heavy variable immunoglobulin domains were released from the Lamin B1 suppressive environment when SHM was induced in B cells. RNA interference-mediated reduction of Lamin B1 resulted in spontaneous SHM as well as kappa-light chain aberrant surface expression. Finally, Lamin B1 expression level correlated with progression-free and overall survival in chronic lymphocytic leukaemia, and was strongly involved in the transformation of follicular lymphoma. In summary, here we report that Lamin B1 is a negative epigenetic regulator of SHM in normal B-cells and a 'mutational gatekeeper', suppressing the aberrant mutations that drive lymphoid malignancy.
Collapse
MESH Headings
- B-Lymphocytes/pathology
- Cell Line, Tumor
- Chromatin Immunoprecipitation/methods
- Disease Progression
- Humans
- Immunoglobulin Heavy Chains/genetics
- Immunoglobulin Variable Region/genetics
- Lamin Type B/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Lymphoma, Follicular/genetics
- Lymphoma, Follicular/pathology
- Somatic Hypermutation, Immunoglobulin/genetics
Collapse
Affiliation(s)
- T Klymenko
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University, London, UK
| | - J Bloehdorn
- Department of Internal Medicine III, University of Ulm, Ulm, Germany
| | - J Bahlo
- Department I of Internal Medicine, Center for Integrated Oncology Cologne, University Hospital of Cologne, Cologne, Germany
| | - S Robrecht
- Department I of Internal Medicine, Center for Integrated Oncology Cologne, University Hospital of Cologne, Cologne, Germany
| | - G Akylzhanova
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University, London, UK
| | - K Cox
- Academic Unit of Cancer Sciences, Faculty of Medicine, Cancer Research UK Centre and Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
| | - S Estenfelder
- Department of Internal Medicine III, University of Ulm, Ulm, Germany
| | - J Wang
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University, London, UK
| | - J Edelmann
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University, London, UK
| | - J C Strefford
- Academic Unit of Cancer Sciences, Faculty of Medicine, Cancer Research UK Centre and Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
| | - T K Wojdacz
- Academic Unit of Cancer Sciences, Faculty of Medicine, Cancer Research UK Centre and Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
- Aarhus Institute of Advanced Studies, Aarhus University, Aarhus, Denmark
| | - K Fischer
- Department I of Internal Medicine, Center for Integrated Oncology Cologne, University Hospital of Cologne, Cologne, Germany
| | - M Hallek
- Department I of Internal Medicine, Center for Integrated Oncology Cologne, University Hospital of Cologne, Cologne, Germany
| | - S Stilgenbauer
- Department of Internal Medicine III, University of Ulm, Ulm, Germany
| | - M Cragg
- Academic Unit of Cancer Sciences, Faculty of Medicine, Cancer Research UK Centre and Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
| | - J Gribben
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University, London, UK
| | - A Braun
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University, London, UK
| |
Collapse
|
9
|
Cramer P, von Tresckow J, Bahlo J, Robrecht S, Al-Sawaf O, Langerbeins P, Engelke A, Fink A, Fischer K, Seiler T, von Weikersthal L, Hebart H, Kreuzer K, Ritgen M, Kneba M, Wendtner C, Stilgenbauer S, Eichhorst B, Hallek M. BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G) AND VENETOCLAX (A) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_5] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- P. Cramer
- Department I of Internal Medicine and German CLL Study Group; University of Cologne; Cologne Germany
| | - J. von Tresckow
- Department I of Internal Medicine and German CLL Study Group; University of Cologne; Cologne Germany
| | - J. Bahlo
- Department I of Internal Medicine and German CLL Study Group; University of Cologne; Cologne Germany
| | - S. Robrecht
- Department I of Internal Medicine and German CLL Study Group; University of Cologne; Cologne Germany
| | - O. Al-Sawaf
- Department I of Internal Medicine and German CLL Study Group; University of Cologne; Cologne Germany
| | - P. Langerbeins
- Department I of Internal Medicine and German CLL Study Group; University of Cologne; Cologne Germany
| | - A. Engelke
- Department I of Internal Medicine and German CLL Study Group; University of Cologne; Cologne Germany
| | - A.M. Fink
- Department I of Internal Medicine and German CLL Study Group; University of Cologne; Cologne Germany
| | - K. Fischer
- Department I of Internal Medicine and German CLL Study Group; University of Cologne; Cologne Germany
| | - T. Seiler
- Department III of Internal Medicine; University Hospital Munich, Ludwig-Maximilians University, Campus Großhadern; Munich Germany
| | | | - H. Hebart
- Center for Internal Medicine; Stauferklinikum Schwäbisch Gmünd; Mutlangen Germany
| | - K.A. Kreuzer
- Department I of Internal Medicine and German CLL Study Group; University of Cologne; Cologne Germany
| | - M. Ritgen
- Department II of Internal Medicine; University of Schleswig-Holstein; Campus Kiel, Kiel Germany
| | - M. Kneba
- Department II of Internal Medicine; University of Schleswig-Holstein; Campus Kiel, Kiel Germany
| | - C.M. Wendtner
- Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing; Munich Germany
| | - S. Stilgenbauer
- Department III of Internal Medicine; University Hospital Ulm; Ulm Germany
| | - B. Eichhorst
- Department I of Internal Medicine and German CLL Study Group; University of Cologne; Cologne Germany
| | - M. Hallek
- Department I of Internal Medicine and German CLL Study Group; University of Cologne; Cologne Germany
| |
Collapse
|
10
|
Al-Sawaf O, Bahlo J, Fischer K, Herling C, Bergmann M, Fink A, von Tresckow J, Langerbeins P, Cramer P, Stilgenbauer S, Wendtner C, Eichhorst B, Hallek M, Goede V. CHARACTERISTICS, TREATMENT, AND OUTCOMES OF ≥ 80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_88] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- O. Al-Sawaf
- Department I of Internal Medicine, German CLL Study Group; University Hospital of Cologne; Cologne Germany
| | - J. Bahlo
- Department I of Internal Medicine, German CLL Study Group; University Hospital of Cologne; Cologne Germany
| | - K. Fischer
- Department I of Internal Medicine, German CLL Study Group; University Hospital of Cologne; Cologne Germany
| | - C. Herling
- Department I of Internal Medicine, German CLL Study Group; University Hospital of Cologne; Cologne Germany
| | - M. Bergmann
- Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine; Klinikum Schwabing; Munich Germany
| | - A.M. Fink
- Department I of Internal Medicine, German CLL Study Group; University Hospital of Cologne; Cologne Germany
| | - J. von Tresckow
- Department I of Internal Medicine, German CLL Study Group; University Hospital of Cologne; Cologne Germany
| | - P. Langerbeins
- Department I of Internal Medicine, German CLL Study Group; University Hospital of Cologne; Cologne Germany
| | - P. Cramer
- Department I of Internal Medicine, German CLL Study Group; University Hospital of Cologne; Cologne Germany
| | - S. Stilgenbauer
- Department III of Internal Medicine; University Hospital Ulm; Ulm Germany
| | - C.M. Wendtner
- Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine; Klinikum Schwabing; Munich Germany
| | - B. Eichhorst
- Department I of Internal Medicine, German CLL Study Group; University Hospital of Cologne; Cologne Germany
| | - M. Hallek
- Department I of Internal Medicine, German CLL Study Group; University Hospital of Cologne; Cologne Germany
| | - V. Goede
- Department I of Internal Medicine, German CLL Study Group; University Hospital of Cologne; Cologne Germany
| |
Collapse
|
11
|
Maurer C, Langerbeins P, Bahlo J, Cramer P, Fink AM, Pflug N, Engelke A, von Tresckow J, Kovacs G, Stilgenbauer S, Wendtner CM, Müller L, Ritgen M, Seiler T, Fischer K, Hallek M, Eichhorst B. Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL. Leukemia 2016; 30:2019-2025. [PMID: 27133817 DOI: 10.1038/leu.2016.113] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2015] [Revised: 03/23/2016] [Accepted: 04/05/2016] [Indexed: 12/15/2022]
Abstract
This study aimed to assess the frequency of and the contributing factors for second primary malignancies (SPMs) and Richter's transformations (RTs) following first-line treatment of chronic lymphocytic leukemia within four phase II/III trials of the GCLLSG evaluating fludarabine (F) vs F+cyclophosphamide (FC), chlorambucil vs F, FC without or with rituximab, and bendamustine+R (BR). Among 1458 patients, 239 (16.4%) experienced either an SPM (N=191) or a RT (N=75). Solid tumors (N=115; 43.2% of all second neoplasias) appeared most frequently, followed by RTs (N=75; 28.2%). Patients showed a 1.23-fold increased risk of solid tumors in comparison to the age-matched general population from the German cancer registry. Age>65 (hazard ratio (HR) 2.1; P<0.001), male sex (HR 1.7; P=0.01), co-morbidities (HR 1.6; P=0.01) and number of subsequent treatments⩾1 (HR 12.1; P<0.001) showed an independent adverse prognostic impact on SPM-free survival. Serum thymidine kinase>10 U/l at trial enrollment (HR 3.9; P=0.02), non-response to first-line treatment (HR 3.6; P<0.001) and number of subsequent treatments⩾1 (HR 30.2; P<0.001) were independently associated with increased risk for RT.
Collapse
Affiliation(s)
- C Maurer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany
| | - P Langerbeins
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany
| | - J Bahlo
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany
| | - P Cramer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany
| | - A M Fink
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany
| | - N Pflug
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany
| | - A Engelke
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany
| | - J von Tresckow
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany
| | - G Kovacs
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany
| | - S Stilgenbauer
- Department of Internal Medicine III, University of Ulm, Ulm, Germany
| | - C-M Wendtner
- Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany
| | - L Müller
- Oncology Leer, Practice for Hematology and Oncology, Leer, Germany
| | - M Ritgen
- Second Department of Medicine, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - T Seiler
- Department of Medicine III, University Hospital Großhadern/LMU München, Munich, Germany
| | - K Fischer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany
| | - M Hallek
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.,Cluster of Excellence in Cellular Stress Responses in Aging-associated Diseases, Univeristy of Cologne, Cologne, Germany
| | - B Eichhorst
- Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany
| |
Collapse
|
12
|
Elter T, James R, Busch R, Winkler D, Ritgen M, Böttcher S, Kahl C, Gassmann W, Stauch M, Hasan I, Staib P, Fischer K, Fink AM, Bahlo J, Bühler A, Döhner H, Wendtner CM, Stilgenbauer S, Engert A, Hallek M. Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia. Leukemia 2012; 26:2549-52. [DOI: 10.1038/leu.2012.129] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|